Growth Differentiation Factor-15 (GDF-15) as a Predictor of Major Adverse Cardiac Event in Acute Myocardial Infarction Patients

Annisa Tridamayanti, Trisulo Wasyanto, Ahmad Yasa’

Abstract


Background: Growth Differentiation Factor-15 (GDF-15) has emerged as a biomarker that capable to predicting cardiovascular events. Recent studies suggest that GDF-15 is elevated in patients with acute myocardial infarction (AMI), but the prognostic remains incompletely defined. This study aimed to investigate the role  of GDF-15 levels with major cardiac adverse events (MACE) on three months follow up in patients with AMI. Methods: This cohort study was conducted from November 2020 until May 2021 at Dr. Moewardi Hospital. GDF-15 was measured at admission, clinical data was collected and 3 months follow up events was registered. Prognostic value of GDF-15 and hazard ratio between high and low GDF-15 level were analyzed. Results: A total of 64 AMI patients were included in this study. MACE at three months follow-up occurred in 26.5% of patients. In multivariate analysis, GDF-15 was independently associated with risk of MACE at 3 months follow up (OR 1.501; p = 0.003). The cut-off point value of GDF-15 was analyzed with the ROC curve, obtained 2256 pg/mL which has a sensitivity of 94.1% and a specificity of 73.8% (area under the curve (AUC) 86.2%; 95% CI 0.768-0.956). Risk model with Kapplan Meier showed significant association between high GDF-15 levels (≥ 2256 pg/mL) and the incidence of MACE at 3 months follow up (HR 12.029; 95% CI 3.429- 42.197; p <0.001) Conclusion: In patients with AMI, high level of GDF-15 was significantly associated with the risk of MACE at 3 months of observation.


Keywords


cute myocardial infarction; growth differentiation factor-15; major adverse cardiac event

References


Benjamin EJ, Virani SS, Callaway CW, et al. American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2018 Update: A Report From the American Heart Association. Circulation. 2018;137(12):e67-e492.

Wasyanto T, Tridamayanti A. Blood urea nitrogen as a predictor of in-hospital mortality in acute coronary syndrome patients. Indones J Med. 20194(3): 241-51.

Tzikas S, Palapies L, Bakogiannis C, et al. GDF-15 predicts cardiovascular events in acute chest pain patients. PLoS One. 2017;12(8):e0182314.

Li JJ, Liu J, Lupino K, Liu X, Zhang L, Pei L. Growth differentiation factor 15 maturation requires proteolytic cleavage by PCSK3, -5, and -6. Mol Cell Biol. 2018;38(21):e00249-18.

Wang X, Chen LL, Zhang Q. Increased serum level of growth differentiation factor 15 (GDF-15) is associated with coronary artery disease. Cardiovasc Ther. 2016;34(3):138-43.

Eggers KM, Kempf T, Lagerqvist B, et al. Growth-differentiation factor-15 for long-term risk prediction in patients stabilized after an episode of non-ST-segment-elevation acute coronary syndrome. Circ Cardiovasc Genet. 2010;3(1):88-96.

Kempf T, von Haehling S, Peter T, et al. Prognostic utility of growth differentiation factor-15 in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1054-60.

Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. J Am Coll Cardiol. 2018;72(18):2231-64.

Peiró ÓM, García-Osuna Á, Ordóñez-Llanos J, et al. Long-term prognostic value of growth differentiation factor-15 in acute coronary syndromes. Clin Biochem. 2019;73:62-9.

Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009;30(9):1057-65.

Eitel I, Blase P, Adams V, et al. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance. Heart. 2011;97(8):632-40.

Bonaca MP, Morrow DA, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011;31(1):203-10.

Hagström E, James SK, Bertilsson M, et al. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. Eur Heart J. 2016;37(16):1325-33.

Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115(8):962-71.

Walter J, Nestelberger T, Boeddinghaus J, et al. Growth differentiation factor-15 and all-cause mortality in patients with suspected myocardial infarction. Int J Cardiol. 2019;292:241-5.

Wallentin L, Lindhagen L, Ärnström E, et al. Early invasive versus non-invasive treatment in patients with non-ST-elevation acute coronary syndrome (FRISC-II): 15 year follow-up of a prospective, randomised, multicentre study. Lancet. 2016;388(10054):1903-11.

Cotter G, Voors AA, Prescott MF, et al. Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. Eur J Heart Fail. 2015;17(11):1133-43.

Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116(14):1540-8.

Wallentin L, Lindholm D, Siegbahn A, et al. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2014;129(3):293-303.

Tentzeris I, Farhan S, Freynhofer MK, et al. Usefulness of elevated levels of growth differentiation factor-15 to classify patients with acute coronary syndrome having percutaneous coronary intervention who would benefit from high-dose statin therapy. Am J Cardiol. 2017;120(5):747-52.


Full Text: PDF

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.